Lenalidomida Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to enhanced immune cell activity, reduced cytokine production, and inhibition of angiogenesis, which together produce antitumor effects.

The specific dose of Lenalidomida Grindeks is individualized and determined by the prescribing physician based on the patient’s condition, disease stage, renal function, and other clinical factors. Patients should follow the dosing instructions provided by their healthcare professional.

Lenalidomida Grindeks is classified as pregnancy Category X because it is teratogenic and can cause fetal harm. It should not be used by pregnant women or women who may become pregnant. Breastfeeding is also contraindicated, as the drug can be excreted in milk and affect the infant.

To order Lenalidomida Grindeks, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lenalidomide is a next‑generation immunomodulatory drug that offers greater potency and a more favorable safety profile compared with its predecessor thalidomide. While both target cereblon, lenalidomide typically results in fewer neuropathic side effects and stronger anti‑angiogenic activity, making it the preferred choice for many hematologic malignancies.

Lenalidomida Grindeks should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Lenalidomida Grindeks is administered orally, usually as whole tablets or capsules, with or without food as directed by the prescriber. Patients should swallow the medication whole and avoid crushing or chewing unless specifically instructed, to maintain proper absorption and efficacy.

The most serious risks include venous thromboembolism, severe neutropenia or other cytopenias that increase infection risk, and teratogenic effects that can cause birth defects. Patients should be monitored regularly for blood count changes and advised to use effective contraception throughout treatment and for a defined period after discontinuation.

Lenalidomida Grindeks should not be used by pregnant women, individuals planning to become pregnant, or those who are breastfeeding. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any of its excipients, and caution is advised in severe renal impairment without appropriate dose adjustment.